Literature DB >> 17311903

Analysis of response to infliximab in ankylosing spondylitis according to the axial and/or peripheral involvement: autoantibodies and drop outs are more frequent in the peripheral subset.

Marco Maria Lizzio, Giusy Peluso, Angelo Zoli, Elisa Gremese, Barbara Tolusso, GianFranco Ferraccioli.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17311903      PMCID： PMC1855993          DOI： 10.1136/ard.2006.065052

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL.

Authors:  C S Via; A Shustov; V Rus; T Lang; P Nguyen; F D Finkelman
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

Review 2.  Thoughts concerning the early diagnosis of ankylosing spondylitis and related diseases.

Authors:  M A Khan
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

3.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Authors:  P E Lipsky; D M van der Heijde; E W St Clair; D E Furst; F C Breedveld; J R Kalden; J S Smolen; M Weisman; P Emery; M Feldmann; G R Harriman; R N Maini
Journal:  N Engl J Med       Date:  2000-11-30       Impact factor: 91.245

4.  Cross-regulation of TNF and IFN-alpha in autoimmune diseases.

Authors:  A Karolina Palucka; Jean-Philippe Blanck; Lynda Bennett; Virginia Pascual; Jacques Banchereau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-22       Impact factor: 11.205

5.  Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial.

Authors:  J Braun; J Brandt; J Listing; A Zink; R Alten; W Golder; E Gromnica-Ihle; H Kellner; A Krause; M Schneider; H Sörensen; H Zeidler; W Thriene; J Sieper
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

Review 6.  Autoimmunity and anti-TNF-alpha agents.

Authors:  Fabiola Atzeni; Maurizio Turiel; Franco Capsoni; Andrea Doria; Pierluigi Meroni; Piercarlo Sarzi-Puttini
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

7.  Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).

Authors:  Désirée van der Heijde; Ben Dijkmans; Piet Geusens; Joachim Sieper; Kimberly DeWoody; Paul Williamson; Jürgen Braun
Journal:  Arthritis Rheum       Date:  2005-02

8.  Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.

Authors:  C Eriksson; S Engstrand; K-G Sundqvist; S Rantapää-Dahlqvist
Journal:  Ann Rheum Dis       Date:  2004-08-05       Impact factor: 19.103

9.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.

Authors:  S Garrett; T Jenkinson; L G Kennedy; H Whitelock; P Gaisford; A Calin
Journal:  J Rheumatol       Date:  1994-12       Impact factor: 4.666

10.  Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

Authors:  Loreto Carmona; Juan J Gómez-Reino
Journal:  Arthritis Res Ther       Date:  2006-04-18       Impact factor: 5.156
  10 in total
  1 in total

1.  Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis.

Authors:  Jose Ramon Maneiro; Alejandro Souto; Eva Salgado; Antonio Mera; Juan J Gomez-Reino
Journal:  RMD Open       Date:  2015-02-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.